NIH/NHLBI Resources

NHLBI has in-house SBIR/STTR expertise and resources, such as assistance with intellectual property, regulatory, and reimbursement issues, biomedical technology development, and early-stage financing.

BioLINCC is a centralized biorepository and data repository with 4.9 million specimens from 73 unique collections.

GTRP facilitates the translation of gene therapy research into clinical interventions.

SMARTT provides preclinical development, manufacturing, pharmacology/toxicology studies, and regulatory affairs support, but does not support drug discovery or clinical trials.

PACT has one coordinating center and five cell processing facilities, and services offered span preclinical and Phase I studies, including toxicity and dose studies needed for IND filing.

NHLBI's Dr. Gary N. Robinson provides information and assistance for a range of matters related to business development.

NHLBI's Luis Gutierrez and Dr. Steve Wolpe offer one-stop shopping for early commercial development, competitive analysis, and transactions resources.

NHLBI's Dr. Chris Sasiela offers regulatory affairs education and strategy development assistance for NHLBI investigators engaged in biomedical product development

General Intellectual Property resources can be found here.

This NIH Center strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. (Programs include BrIDGs, TRND, TDP, MLP)

The BrIDGs program (part of NCATS) offers preclinical study resources free of charge to investigators. It is open to academics, nonprofit organizations, and SBIR-eligible businesses.

The MLP program (part of NCATS) offers investigators access to large-scale small molecule screening, as well as medicinal chemistry and informatics needed to identify chemical probes.

The TDP (part of NCATS) seeks to discover new therapeutic uses for existing drugs through partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development.

The TRND program (part of NCATS) offers drug development through collaboration between NCATS and NIH-funded laboratories. Eligible projects are small molecules or proteins in preclinical development to treat FDA orphan diseases or World Health Organization (WHO) neglected tropical diseases.